| Primary |
| Product Used For Unknown Indication |
30.8% |
| Acute Myeloid Leukaemia |
18.5% |
| Acute Lymphocytic Leukaemia |
16.9% |
| Acute Leukaemia |
4.7% |
| Prophylaxis |
4.5% |
| Lymphocytic Leukaemia |
3.8% |
| Bone Marrow Conditioning Regimen |
3.4% |
| Prophylaxis Against Graft Versus Host Disease |
3.0% |
| Myelodysplastic Syndrome |
2.2% |
| Haematological Malignancy |
1.7% |
| Stem Cell Transplant |
1.5% |
| Nausea |
1.4% |
| Infection Prophylaxis |
1.4% |
| Drug Use For Unknown Indication |
1.3% |
| Acute Lymphocytic Leukaemia Recurrent |
1.1% |
| Myeloid Leukaemia |
0.9% |
| Antifungal Prophylaxis |
0.9% |
| Hypertension |
0.7% |
| Leukaemia |
0.7% |
| Vomiting |
0.7% |
|
| Death |
17.4% |
| Thrombocytopenia |
12.2% |
| Sepsis |
8.0% |
| Neoplasm Malignant |
5.9% |
| Vomiting |
5.9% |
| Acute Lymphocytic Leukaemia |
4.9% |
| Tumour Lysis Syndrome |
4.7% |
| Neutropenia |
4.2% |
| Infection |
4.0% |
| Multi-organ Failure |
4.0% |
| White Blood Cell Count Decreased |
4.0% |
| Pancytopenia |
3.3% |
| Disease Progression |
3.1% |
| Renal Failure |
3.1% |
| Febrile Neutropenia |
2.8% |
| Acute Myeloid Leukaemia |
2.6% |
| Septic Shock |
2.6% |
| Venoocclusive Disease |
2.6% |
| Transaminases Increased |
2.4% |
| Venoocclusive Liver Disease |
2.4% |
|
| Secondary |
| Product Used For Unknown Indication |
32.4% |
| Acute Lymphocytic Leukaemia |
15.9% |
| Acute Myeloid Leukaemia |
14.0% |
| Bone Marrow Conditioning Regimen |
6.6% |
| Prophylaxis |
3.8% |
| Acute Leukaemia |
3.0% |
| Prophylaxis Against Graft Versus Host Disease |
3.0% |
| Stem Cell Transplant |
3.0% |
| Nausea |
2.4% |
| Infection Prophylaxis |
2.0% |
| Atrial Fibrillation |
1.9% |
| Lymphocytic Leukaemia |
1.7% |
| Myelodysplastic Syndrome |
1.5% |
| Infection |
1.4% |
| Non-hodgkin's Lymphoma |
1.4% |
| Vomiting |
1.4% |
| Haematological Malignancy |
1.3% |
| Langerhans' Cell Histiocytosis |
1.2% |
| Pain |
1.1% |
| Acute Lymphocytic Leukaemia Recurrent |
1.0% |
|
| Thrombocytopenia |
14.7% |
| Neutropenia |
9.3% |
| Neoplasm Malignant |
7.0% |
| Pancytopenia |
7.0% |
| Febrile Neutropenia |
6.2% |
| Fibrosis |
6.2% |
| Sepsis |
6.2% |
| Bone Marrow Failure |
5.4% |
| Tumour Lysis Syndrome |
4.7% |
| Acute Leukaemia |
3.9% |
| Acute Lymphocytic Leukaemia |
3.9% |
| Death |
3.9% |
| Acute Myeloid Leukaemia |
3.1% |
| Histiocytosis Haematophagic |
3.1% |
| Pneumonia |
3.1% |
| Varicella |
3.1% |
| Acute Myeloid Leukaemia Recurrent |
2.3% |
| Acute Respiratory Distress Syndrome |
2.3% |
| Blood Pressure Fluctuation |
2.3% |
| Cerebral Haemorrhage |
2.3% |
|
| Concomitant |
| Drug Use For Unknown Indication |
83.3% |
| Myelodysplastic Syndrome |
16.7% |
|
| Myelodysplastic Syndrome Transformation |
100.0% |
|
